Commercialisation of biotechnology: Do dedicated public policies matter?

Christien Enzing, Annelieke van der Giessen and Sander Kern

Science and Public Policy, 2004, vol. 31, issue 5, 371-383

Abstract: National governments are often confronted with the questions whether generic policy instruments are sufficient to support technology development and innovation and what justifies the introduction of instruments that focus on one specific technology. This article investigates the relationship between the commercial performance in biotechnology of 14 EU Member States and the presence of instruments that stimulate and support commercialisation of biotechnology in these countries. Our findings contradict the proposition that countries with dedicated biotech instruments show better commercialisation performance in biotechnology than countries without such instruments. Instead, success is more likely to be determined by the systemic character of public policies that address all elements of the innovation system, including instruments that stimulate the life sciences knowledge base and its commercialisation. Copyright , Beech Tree Publishing.

Date: 2004
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://hdl.handle.net/10.3152/147154304781779868 (application/pdf)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:oup:scippl:v:31:y:2004:i:5:p:371-383

Access Statistics for this article

Science and Public Policy is currently edited by Nicoletta Corrocher, Jeong-Dong Lee, Mireille Matt and Nicholas Vonortas

More articles in Science and Public Policy from Oxford University Press
Bibliographic data for series maintained by Oxford University Press ().